CaPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor) Study

CEASAR (Comparative Effectiveness Analyses of Surgery and Radiation in localized prostate cancer) Study

JOURNAL ARTICLES BY YEAR OF PUBLICATION

Click PubMed ID for copyright-compliant access to publications via UC-elinks

1996

1997

1998


**1999**


**2000**


Comment *Urology.* 2001 Feb;57(2):394-5. PMID: 11246646


15. Lubeck DP, Litwin MS, Henning JM, Mathias SD, Bloor L and Carroll PR. An instrument to measure patient satisfaction with healthcare in an observational database: Results of a validation study using data from CaPSURE. *Am J Manag Care.* 2000 Jan;6(1):70-76. PMID: 11009748
2001


2002


2003


32. Cooperberg MR, Grossfeld GD, Lubeck DP, and Carroll PR. National practice patterns and time trends in androgen ablation for localized prostate cancer. *J Natl Cancer Inst*. 2003 Jul 2;95(13):981-989. This paper has been cited over 100 times since publication. PMID: 12837834


41. Latini DM, Downs TM, Grossfeld GD, Lubeck DP, Mehta SS and Carroll PR. Disease recurrence after radical prostatectomy for patients with high-risk disease: Data from CaPSURE and UCSF. *Amer J of Urol Rev.* 2003;1:62-71. [Request article from jcowan@urology.ucsf.edu]


**2004**

45. Arredondo SA, Downs TM, Lubeck DP, Pasta DJ, Silva, SJ, Wallace KL and Carroll PR. Watchful waiting and health related quality of life for patients with localized prostate cancer: Data from CaPSURE. *J Urol.* Nov;172(5 Pt 1):1830-4. *This paper was featured for CME credits.* PMID: 15540732


49. Cooperberg MR, Broering JM, Litwin MS, Lubeck DP, Mehta SS, Henning JM, Carroll PR and the CaPSURE Investigators. The contemporary management of prostate cancer in the United States: Lessons from the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE), a national disease registry. *J Urol*. 2004 Apr;171(4):1393-401. This paper has been cited over 100 times since publication. PMID: 15017184


2005


60. Cooperberg MR, Pasta DJ, Elkin EP, Litwin MS, Latini DM, DuChane J, Carroll PR. The University of California, San Francisco cancer of the prostate risk assessment score: A


2006


2007


2008


2009


**2010**


134. Moses KA, Paciorek AT, Penson DF, Carroll PR, Master VA. Impact of Ethnicity on Primary Treatment Choice and Mortality in Men With Prostate Cancer: Data From CaPSURE. *J Clin Oncol.* 2010 28(6):1069-74. PMID: 20100957


2011


147. Reese AC, Fradet V, Whitson JM, Davis CB, Carroll PR. Poor agreement of prostate specific antigen doubling times calculated using ultrasensitive versus standard prostate specific antigen values: important impact on risk assessment. *J Urol.* 2011;186(6):2228-32. PMID: 22014796


2012


2013


2014


2015


2016

2017


2018


2019


patient-level outcomes and costs across prostate cancer treatments with urinary problems. Am J 
Men’s Health. 2019 Mar-Apr;13(2):1557988319835326. PMID: 30836832

191. Ten Ham RMT, Broering JM, Cooperberg M, Carroll P, Wilson LS. Understanding the major 
factors affecting response shift effects on health-related quality of life: What the Then-Test 
ahead of print. PMID: 31796344

192. Zuniga KB, Zhao S, Kenfield SA, Cedars B, Cowan JE, Van Blarigan EL, Broering JM, 
Carroll PR, Chan JM. Trends in complementary and alternative medicine use among patients 

CEASAR papers

LE, Phillips S, Stroup AM, Wu XC, Penson DF. Association between radiation therapy, surgery, 
or observation for localized prostate cancer and patient-reported outcomes after 3 years. JAMA.  
2017 Mar 21;317(11):1126-40. PMID: 28324093

Barocas DA, Chen VW, Cooperberg MR, Goodman M, Graff JJ, Greenfield S, Hamilton AS, 
AM, Wu XC, Penson DF. Using a population-based observational cohort study to address 
2013 Jul;2(4);445–60. PMID: 24236685

Friedly JL, Bauer Z, Comstock BA, DiMango E, Ferrara A, Huang SS, Israel E, Jarvik JG, 
Nierenberg AA, Ong MK, Penson DF, Smith-Bindman R, Stillman AE, Vollmer WM, Warren SM, 
Zhan C, Hsia DC, Trontell A. Challenges conducting comparative effectiveness research: the 
Clinical and Health Outcomes Initiative in Comparative Effectiveness (CHOICE). Comparative 
Effectiveness Research. 2014;4;1-12. PMID: None DOI: http://dx.doi.org/10.2147/CER.S59136

O’Neil B, Koyama T, Alvarez J, Conwill RM, Albertsen PC, Cooperberg MR, Goodman M, 
Paddock LE, Wu XC, Stephenson RA, Resnick MJ, Barocas DA, Penson DF. The comparative 
harms of open and robotic prostatectomy in population based samples. J Urol. 2016 Feb;195 
(2):321-9. PMID: 26343985

Resnick MJ, Barocas DA, Morgans AK, Phillips SE, Chen VW, Cooperberg MR, Goodman M, 
T, Penson DF. Contemporary prevalence of pretreatment urinary, sexual, hormonal, and bowel 
dysfunction: Defining the population at risk for harms of prostate cancer treatment. Cancer. 2014 
Apr 15;120(8):1263-71. PMID: 24510400

Resnick MJ, Morgans AK, Phillips SE, Koyama T, Albertsen PC, Cooperberg MC, Goodman M, 
Greenfield S, Hamilton AS, Hoffman KE, Hoffman RM, Kaplan SH, McCullum D, Paddock LE, 
Standord JL, Stroup AM, Wu XC, Penson DF. The Evolution of Self-Reported Urinary and
Sexual Dysfunction over the last two decades: Implications for Comparative Effectiveness Research. *Eur Urol* 2015;67(6):1019-25. PMID: 25174325 DOI: [http://dx.doi.org/10.1016/j.eururo.2014.08.035](http://dx.doi.org/10.1016/j.eururo.2014.08.035)


**Related papers**


